All News

22 January 2010

Arzerra (Ofatumumab) Receives Positive Opinion for Conditional Approval in Europe for Refractory Chronic Lymphocytic LeukaemiaAntibodies

21 January 2010

Amgen Presents Complete Results From Two Pivotal Phase 3 Studies of Vectibix(R) at Gastrointestinal Cancers SymposiumAntibodies

20 January 2010

Fully Human Monoclonal Anti-TNF-alpha Antibody HUMIRA Receives Approval as Japan’s First Biological Agent for PsoriasisAntibodies

19 January 2010

Perseid Achieves Preclinical Milestone Under Collaboration with Astellas for CTLA-4 ProgramAntibodies

19 January 2010

Enrollment Open for Clinical Trial of Cytolin, a Novel Immune Therapy from CytoDyn for Treating Early HIV InfectionAntibodies

19 January 2010

Biotie reports positive top-line data from clinical study with VAP-1 antibody in rheumatoid arthritis patients – BTT-1023 is well tolerated and shows signals of therapeutic activityAntibodies

19 January 2010

MorphoSys Enrolls First Patient in Phase 1b/2a Clinical Trial for MOR103 Program in Rheumatoid ArthritisAntibodies

14 January 2010

Kenta Biotech Announces Collaboration with Rentschler Biotechnologie for Antibody Development Against Hospital-Acquired InfectionsAntibodies

14 January 2010

STELARA Shows Greater Efficacy than Etanercept for Treatment Of Moderate-To-Severe Plaque PsoriasisAntibodies

11 January 2010

Sanofi Pasteur Partners with KaloBios on Novel Biologic for the Prevention and Treatment of Pseudomonas aeruginosa InfectionsAntibodies

11 January 2010

ABLYNX SUCCESSFULLY GENERATES NANOBODIES AGAINST AN ION CHANNEL AND ANNOUNCES NEW GPCR PROGRAMMEAntibodies

11 January 2010

Sorrento Therapeutics Announces Antibody Discovery and Development Alliance for the Prevention and Treatment of MRSA InfectionsAntibodies

11 January 2010

Facet Biotech Announces Enrollment of First Patient in Phase 2 Study of Elotuzumab in Patients With Relapsed Multiple MyelomaAntibodies

11 January 2010

AnaptysBio Announces Agreement with Roche to Develop Novel AntibodiesAntibodies

11 January 2010

Symphogen Publishes Pre-Clinical Data in Cancer Research Demonstrating Superior Efficacy of Anti-EGFR Monoclonal Antibody Combination Sym004Antibodies

11 January 2010

Trubion Pharmaceuticals, Inc. Announces Initiation of a Phase 2 Study of SBI-087 for the Treatment of Rheumatoid Arthritis (RA)Antibodies

11 January 2010

Apogenix Initiates Clinical Phase II Study with its Lead Compound APG101 in GlioblastomaAntibodies

11 January 2010

FDA Approves ACTEMRA® (tocilizumab) for the Treatment of Moderately to Severely Active Rheumatoid ArthritisAntibodies

7 January 2010

Tolerx Completes Enrollment in DEFEND-1, A Phase 3 Type 1 Diabetes Study With OtelixizumabAntibodies

7 January 2010

Prolias Announces Strategic Technology Acquisition for Human Therapeutic AntibodiesAntibodies

7 January 2010

Pfizer and Debiopharm collaborate to co-develop investigational compound tremelimumab (CP-675,206) in advanced melanomaAntibodies

6 January 2010

InNexus Biotechnology Develops New Psoriasis Product Based on Its Skin Permeating Antibody TechnologyAntibodies

4 January 2010

NeoPharm Announces IND Filing for IL13-PE38QQR for the Treatment of Idiopathic Pulmonary FibrosisAntibodies

4 January 2010

First Patient treated in BioInvent’s Phase I Study of the Drug Candidate BI-505 to Treat Multiple MyelomaAntibodies

29 December 2009

Pfizer Discontinues A Phase 3 Trial Of Figitumumab In Non-Small Cell Lung Cancer (NSCLC) For FutilityAntibodies

24 December 2009

MedImmune Replies to FDA Complete Response Letter on MotavizumabAntibodies

22 December 2009

to-BBB and Lundbeck to join forces on brain delivery of antibodies for CNS diseasesAntibodies

22 December 2009

Genentech Submits Supplemental Application to FDA for Lucentis in Patients with Retinal Vein OcclusionAntibodies

22 December 2009

ABLYNX DEMONSTRATES PROOF-OF-CONCEPT BY BIOMARKER FOR ITS ANTI-THROMBOTIC ALX-0081Antibodies

22 December 2009

PDL BioPharma Announces New Licensing Agreement With Eli LillyAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

TSLP Pipeline Review

RNA-Targeted Small Molecules 2019: a landscape analysis of companies, technologies, targets, investors and partners from an industry perspective

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

DLL3-Targeted Immunotherapy Candidates Pipeline Review

CD73 Inhibitor Pipeline Review

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

Adalimumab (Humira) Biosimilars Pipeline Review

Intracellular Targets made druggable by TCR-like Antibodies, TCR Fusion Proteins & Cell-Penetrating Biologics 2018: an industry analysis of technologies, stakeholders, deals & trends

Ustekinumab (Stelara) Biosimilars Pipeline Review